Molecular Target For Breast Carcinoma Epidermal Growth Factor Receptor Type Ⅲ Variant In Clinical Research

Up to now, some disadvantages existing concerning a variety of clinical diagnosis and therapeutics in breast tumor, and how to diagnosis and treat breast tumor in noninvasive way is the hot and difficult point of clinical research. The question is if we could find a breast tumor specific target, to address the diagnosis and treatment problems both. Recent studies have found that the epidermal growth factor receptor typeâ…¢variant (EGFRvâ…¢) plays an important role in tumor occurrence and it expresses only in malignant tumors but not in normal tissues, this character makes EGFRvâ…¢be a potential target in breast tumor diagnosis and therapy.Objective:1. Measuring the quantity expressed by EGFRvâ…¢in breast cancer, we explore the relationship between EGFRvâ…¢and the biological characteristics in human breast tumor, and evaluate the clinicopatholoical importance of EGFRvâ…¢in breast tumor.2. We explore the relationship between EGFRvâ…¢and the prognosis of axillary node-negative breast cancer, providing prognosis judgment for the axillary node-negative breast cancer patients.3. Exploring the feasibility of the EGFRvâ…¢as a target to diagnosis and treat breast cancer in basic theory and clinical theory.Methods:1. UltraSensitiveTM immunohistochemistry (IHC) S-P method was used to detect the expression of EGFRvIII in 108 specimens of human breast cancer tissues and 62 specimens of human hyperplasia breast tissues.2. Using the computerized image analysis and SPSS Statistics to analyze the relationship between the quantity of EGFRvIII expression and the clinicopathology indicators(age, the diameter of tumor, histology classification, axillary lymph node metastasis, ER,PR,Her-2,Ki-67) respectively.3.Using Kaplan-Meier survival analysis and Log-rank test to evaluate the association of clinical parameter and prognosis for 41 node-negative breast cancer patients whose necessary follow-update were available. Cox multivariate prognosis analysis was performed.Results:1.It was found that in breast cancer, EGFRvâ…¢was mildly expressed in 25.93%(28/108), moderately in 25%(27/108), intensively in 5.56%(6/108), and there was no detection in breast hyperplasia tissues.2. Postitive rate of EGFRvâ…¢in breast cancer was significantly correlated with the diameter of tumor, axillary lymph node metastasis, histology classification, ER and Her-2 (P<0.05),but no correlated with the age, PR and Ki-67 (P>0.05).3. The 5-year DFS was 90.4% and OS was 95.12% of 41 axillary node-negative breast cancer patients. There is obviously distinction of survival curves between EGFRvâ…¢negative group and positive group, and we could find that the 5-year DFS which EGFRvâ…¢negative group was prominently higher than positive group (P<0.05). Histology classification, ER and Her-2 are the risk factors which affect the survival time of axillary lymph node-negative breast cancer.Conclusions:1.Our research has proved that EGFRvâ…¢expresses only in breast cancers but un-find in breast hyperplasia tissues, suggests that EGFRvâ…¢can be used as a diagnostic indicator for breast cancer detection, thus it may be an ideal specific target for breast cancer treatment.2.EGFRvâ…¢plays a crucial role in breast cancer development, proliferation, local infiltration, lymph node-negative metastasis and recurrence, so detecting the expression of EGFRvâ…¢in breast cancer tissues and assessing the biological specialty, such as histology classification, the diameter of tumor, ER and Her-2, would help us to understand the laws of development and metastasis of breast cancer and to estimate its prognosis.